Analyzing the patent and trademark challenges faced by 503A compounding pharmacies.
Martha M. Rumore, PharmD, RPh, MS, LLM, Esq
Advertisement
Articles by Martha M. Rumore, PharmD, RPh, MS, LLM, Esq
FDA seeks to reduce diversion of pharmaceutical products via sales by unlicensed distributers and tighten up the supply chain by vetting trading partners.
Advertisement
Latest Updated Articles
FDA Proposed Rule: Game Changer For Pharmaceutical Supply ChainPublished: March 25th 2022 | Updated:
Legal Battles Intensify: Pharmaceutical Manufacturers' Lawsuits Targeting Compounding PharmaciesPublished: July 12th 2023 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
Anitocabtagene Autoleucel Demonstrates Deep, Durable Responses and Improved MRD-Negativity in RRMM
2
Inclisiran, PCSK9s Elicits Sustained LDL-C Reductions in Familial Hypercholestrolemia
3
Delayed Statin Initiation Following Detection of High LDL-C Raises Risk of Heart Attack
4
Biolinq Shine Receives FDA De Novo Classification as First Multi-Analyte Wearable for Type 2 Diabetes
5
